32 / 46
3. Largos respondedores
con Pazopanib
•
Los datos publicados con pazopanib son más escasos y se limitan a:
Un subanalisis de estudio COMPARZ [1]
Un trabajo publicado con pacientes de vida real [2]
1. Tannir, N; Porta, C ; Gruenwald, V. Long-term response and time to response to pazopanib (PAZ) and sunitinib (SUN) in metastatic renal cell
carcinoma (mRCC): COMPARZ subanalysis. Journal of Clinical Oncology, supl. Supplement 1 35.15 American Society of Clinical Oncology. 2017.
2. Park, J; Jiao, X; Wilson, T. Predictors of long-term responders in patients treated with pazopanib for advanced renal cell carcinoma (aRCC).
Journal of Clinical Oncology, supl. Supplement 1 35.6 American Society of Clinical Oncology. 2017.